Decision to list rehabilitation products supplied by Protec Solutions Limited
We are pleased to announce the approval of a listing agreement with Protec Solutions Limited for the supply of rehabilitation equipment, patient positioning products and supports.
Proposal to list medical devices by Ultramedix Australasia Limited
PHARMAC is seeking feedback on a proposal to list an obstetrics and gynaecology medical device in Part III of the Section H of the Pharmaceutical Schedule from 1 May 2020 through a provisional agreement with Ultramedix Australasia Limited.
Closes: 4pm Monday 2 March 2020.
Proposal to list medical devices supplied by Mӧlnlycke Health Care Pty Ltd
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports, and surgical drapes, gowns and procedure packs supplied by Mӧlnlycke Health Care Pty Ltd in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
Closes: 4pm on Friday 28 February 2020.
Proposal to list orthopaedic implants and associated products supplied by Surgical Innovations Limited
PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020, through a listing agreement with Surgical Innovations Limited.
Closes: 4pm Tuesday, 25 February 2020.
January 2020 tender notification
PHARMAC has resolved not to award any tenders for Sole Subsidised Supply Status or Hospital Supply Status this month.
Proposal to list rehabilitation products supplied by Allied Medical and Amtech
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Allied Medical Limited and Amtech Medical Limited in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
Closes: 4pm on Monday 17 February 2020.
Proposal to fund ivacaftor (Kalydeco) for the treatment of patients with cystic fibrosis with the G551D mutation
We are seeking feedback on a proposal to fund ivacaftor (Kalydeco) for the treatment of cystic fibrosis with the G551D mutation (or other class III gating mutations) from 1 March 2020 through a provisional agreement with Vertex Pharmaceuticals Pty Ltd (Vertex).
Closes: 10am, Monday 10 February 2020.
PHARMAC seeking views on new cystic fibrosis medicine
PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) for people with cystic fibrosis.
Proposal to list orthopaedic implants and associated products supplied by Lifehealthcare Limited
PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020, through a listing agreement with Lifehealthcare Limited.
Closes: 4pm Thursday, 13 February 2020.
Proposal to list rehabilitation products supplied by Active Healthcare and Permobil
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Active Healthcare (NZ) Limited and Permobil New Zealand Limited in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
Closes: 4pm on Friday 14 February 2020.
Proposal to list medical devices by Hologic (Australia & New Zealand) Pty Limited
PHARMAC is seeking feedback on a proposal to list a range of obstetrics and gynaecology products in Part III of Section H of the Pharmaceutical Schedule from 1 March 2020 through a provisional agreement with Hologic (Australia & New Zealand) Pty Limited.
Closes: 4pm on Tuesday 4 February 2020.
PHARMAC considering new medicines for type 2 diabetes
PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes
Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
We are seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate with calcipotriol foam spray (Enstilar) from 1 April 2020, through a provisional agreement with Leo Pharma.
Closes: 5pm, Monday 3 February 2020.
Proposal to fund palbociclib (Ibrance) for advanced breast cancer
We are seeking feedback on a proposal to fund palbociclib (Ibrance) as a first-line and second-line treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer through a provisional agreement with Pfizer New Zealand.
Closes: 5pm, Friday 31 January 2020.
PHARMAC seeking views on new breast cancer medicine
PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer.
RFP - supply of diabetes agents: SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors – ADDENDUM ADDED TO EXTEND SOLE SUPPLY PERIOD
PHARMAC invites proposals for the supply of diabetes agents: SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors in New Zealand.
All proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4pm NZT Monday 16 March 2020 - RFx ID 22162611.
If you have any questions about this RFP, please post these on the Government Electronic Tenders Service (www.gets.govt.nz).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this RFP to be kept up to date.
Proposal to list rehabilitation products supplied by Protec Solutions Limited
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Protec Solutions Limited in Part III of Section H of the Pharmaceutical Schedule from 1 March 2020.
Closes: 4pm on Friday 31 January 2020.
Lamotrigine NPPA data
Response to a request for information on NPPA applications for lamotrigine.
Adalimumab data
Response to a request for information on adalimumab, etanercept, infliximab and secukinumab data.
December 2019 tender notification
PHARMAC has not resolved to award any tenders for Sole Subsidised Supply Status or Hospital Supply Status this month.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Media queries
021 863 342
Media phone is monitored 9am–5pm weekdays
